Fortis Healthcare’s share price is currently around ₹667, reflecting strong momentum and significant outperformance over the past year, with a return of about 49%. The stock recently touched a 52-week high of ₹744.5 and a low of ₹406, indicating a broad trading range and robust investor interest
Analyst sentiment remains bullish, with most forecasts targeting a price range of ₹736 to ₹850 over the next 12 months, suggesting a potential upside of around 10–20% from current levels[3][5][8]. Some projections are even more optimistic, with year-end 2025 targets as high as ₹933 if market conditions remain favorable[4]. Technical indicators currently point to a bullish trend, supporting the positive outlook[5].
Fundamentally, Fortis Healthcare has reported strong financial results, including an 84% year-on-year jump in net profit for Q3 FY2024-25 and a 40% quarterly profit increase, underscoring operational momentum[5][6]. The company trades at a price-to-earnings (PE) ratio of about 65, which is above the sector average, indicating that the stock is priced at a premium due to its growth prospects[5]. The price-to-book (PB) ratio is 3.49, and the dividend yield is modest at 0.24%[5].
In summary, Fortis Healthcare is in a bullish phase, supported by strong earnings growth and positive analyst outlooks. While the stock is trading at a premium valuation, its growth trajectory and sector leadership continue to attract investor interest, with further upside likely if current trends persist
Analyst sentiment remains bullish, with most forecasts targeting a price range of ₹736 to ₹850 over the next 12 months, suggesting a potential upside of around 10–20% from current levels[3][5][8]. Some projections are even more optimistic, with year-end 2025 targets as high as ₹933 if market conditions remain favorable[4]. Technical indicators currently point to a bullish trend, supporting the positive outlook[5].
Fundamentally, Fortis Healthcare has reported strong financial results, including an 84% year-on-year jump in net profit for Q3 FY2024-25 and a 40% quarterly profit increase, underscoring operational momentum[5][6]. The company trades at a price-to-earnings (PE) ratio of about 65, which is above the sector average, indicating that the stock is priced at a premium due to its growth prospects[5]. The price-to-book (PB) ratio is 3.49, and the dividend yield is modest at 0.24%[5].
In summary, Fortis Healthcare is in a bullish phase, supported by strong earnings growth and positive analyst outlooks. While the stock is trading at a premium valuation, its growth trajectory and sector leadership continue to attract investor interest, with further upside likely if current trends persist
עסקה פעילה
43%+ Move 7 years of FD gainsעסקה סגורה: היעד הושג
62%+ ROI, and trend continues smoothly
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.